黄素对22Rv1前列腺癌细胞系的剂量依赖作用
Giovanni Tossetta1, Sonia Fantone2, Elena Marinelli Busilacchi3
1Department of Experimental and Clinical Medicine, Università Politecnica delle Marche, 60126, Ancona, Italy.
Molecular biology reports
|March 26, 2025
概括
低剂量的黄素会诱导前列腺癌细胞的衰老,而高剂量则具有细胞毒性. 这表明黄素在前列腺癌 (PCa) 治疗中使用的个性化方法.
科学领域:
- 在瘤学瘤学.
- 天然化合物 天然化合物
- 细胞生物学 细胞生物学
背景情况:
- 前列腺癌 (PCa) 是老年男性的一种流行癌症.
- 黄素是从长黄 (Curcuma longa) 中获得的,具有抗癌性质.
- 以前的研究表明,关于黄素在PCa中的疗效和毒性,结果各不相同.
研究的目的:
- 为了研究黄素对前列腺癌细胞的剂量依赖作用.
- 评估黄素对细胞周期,细胞死亡和衰老标记物的影响.
主要方法:
- 用不同度的黄素 (5,15,30μM) 治疗22Rv1前列腺癌细胞系.
- 细胞周期进展 (G2/M阶段) 的分析.
- 细胞死亡和衰老标志物的表达的评估 (p21, p16).
主要成果:
- 低剂量黄素诱导了22Rv1细胞的衰老效应.
- 较高度的黄素 (15和30微米) 显示出细胞毒性作用和诱导细胞死亡.
- 黄素治疗增加了所有测试度的p21表达和30μM的p16表达.
结论:
- 黄素对前列腺癌细胞的影响是剂量依赖的,低剂量诱导衰老,高剂量诱导细胞毒性.
- 这些发现支持在PCa护理中使用黄素的个性化策略.
- 黄素可以被视为放射治疗或雄激素剥夺疗法 (ADT) 的辅助疗法.
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


